In focus · trending topic

Licensing Agreements

44 stories · following the connections

Arbutus Announces Corporate Update and First Quarter 2018 Financial Results

By Nasdaq OMXMay 3, 2018, 8:00 PM UTC

Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA

By Nasdaq OMXApr 16, 2018, 11:00 AM UTC

Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases

By Nasdaq OMXApr 11, 2018, 9:24 PM UTC

Vera Bradley Announces New Licensing Agreement for Sleepwear/Loungewear

By Nasdaq OMXMar 14, 2018, 1:01 PM UTC

Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology

By Nasdaq OMXFeb 22, 2018, 9:35 PM UTC

Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™

By Nasdaq OMXFeb 16, 2018, 12:00 PM UTC

Arbutus Enters Exclusivity Agreement with Roivant Sciences

By Nasdaq OMXFeb 15, 2018, 1:50 AM UTC

Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran

By Nasdaq OMXNov 16, 2017, 6:40 PM UTC